Article By:
The Fly
Sunday, February 11, 2024 2:20 PM EDT
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.